EGAGenomicsOtherhttps://ega-archive.org/studies/EGAS00001005935EGAEGA study EGAS00001005935Whole exome sequencing of tumors from the Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent MalignanciesEGArestrictedTeenager, Adolescence, Female Adolescent, Occidental, Individualized, Female Adolescents, Male, Predictive Medicine, Individualized Medicine, Youths, white, Theranostic, Male Adolescents, Personalized, Female, Teenagers, Adolescents, Teen, Programs, Client., Caucasian, P-Health, Youth, Patient, Whites, Personalized Medicine, European, Clients, Theranostics, Medicine, White, P Health, Precision, Male Adolescent, Teens, Predictive, Adolescent, Caucasoid, Caucasiansduplication of the halluces and polydactyly, acetic thiokinase activity, Individualized Medicine, 1-bis(diphenylmethoxy-2'-ethyldimethylammoniumacetoxy)decane dichloride, acetyl-CoA synthetase activity, LACS 1, cfDNA, Circulating, Tumor, acetate to acetyl-CoA, Circulating DNA, Mid(H15), acrocephalosyndactylia, AC, Facl2, acute chest syndrome, responsivity, Cell-Free, 1, Cell-Free Nucleic Acid, Fs(3)Hor, Cell Free Nucleic Acid, treatment, CG9390, DmelCG2684, cirDNA, FACS, Tissue, NTef2, genetic, LACS1, hallux Duplication, acetyl-CoA synthase activity, disease management, Medicine, Therapies, Acs, Schinzel type, ACS, Malignancies, Acyl-CoA synthetase short-chain family member 2, Tumors, Therapy, familial, ACs, Lypla3, Fs(3)Sz11, LYPLA3, Cell Free Ribonucleic Acid, Benign, acetate thiokinase activity, Personalized Medicine, Suggestions, simple tissue, Circulating Nucleic Acids, Cell-Free Deoxyribonucleic Acid, Joubert syndrome 12/15, H15r/nmr2, Acid, Irish Free State, Circulating Cell Free Nucleic Acids, Cell Free Nucleic Acids, Nucleic Acids, follow up, DmelCG9390, Benign Neoplasms, Treatments, Saint Pierre and Miquelon, early, Malignant Neoplasms, 2.3.1.-, Patient, and absence of corpus callosum, Horka, Theranostics, CG2684, Fs(3)Horka, St. Pierre and Miquelon, inherited genetic, GXVPLA2, Acids, acetyl-CoA:corrinoid protein O-acetyltransferase activity, DNA, other neoplasm, LCAT-like lysophospholipase, Lysosomal phospholipase A2, Balearic Islands, Cell-Free Deoxyribonucleic, LPLA2, Neoplasms, acetyl activating enzyme, Circulating Cell Free Nucleic Acid, Benign Neoplasm, C87498, BEST:GH28401, Malignant, acyl-activating enzyme activity, Circulating Cell-Free Nucleic Acid, acute chest syndrome in sickle cell disease, Deoxyribonucleic Acid, A-17, Cell-Free RNA, Miquelon and St. Pierre, Lysophospholipase 3, Acetate--CoA ligase, Precision, DmF2, Cell Free DNA, lod, reactivity, Cell Free Deoxyribonucleic Acid, acetyl-activating enzyme activity, Acetyl-CoA synthetase, Individualized, Malignancy, mental deficiency, los, acetyl CoA synthase activity, Lpla2, Cell-Free Ribonucleic, Circulating Cell-Free Nucleic Acids, AcCoAs, LLPL, Acyl-activating enzyme, Neoplasias, Miquelon and Saint Pierre, acrocephalosyndactyly, Sardinia, DmelCG6634, Clients, ACAS2, acrocallosal syndrome, Predictive, constitutitional genetic, Cancer, Acas1, Cell-Free DNA., Republic of, RNA, CO-methylating acetyl-coenzyme A synthase activity, Malignant Neoplasm, Predictive Medicine, 1-O-acylceramide synthase, Canary Islands, COAA, Joubert syndrome 12, dJ1161H23.1, Personalized, Client, ACECS, Circulating RNA, dACS, short-chain acyl-coenzyme A synthetase activity, 6.2.1.1, H15r, Circulating Nucleic Acid, Nucleic Acid, Neoplasm, Cell Free RNA, Corsica, short chain fatty acyl-CoA synthetase activity, acetyl coenzyme A synthetase activity, postaxial polydactyly, nmr2, AceCS, acetyl-coenzyme A synthase activity, CG6634, cirRNA, Theranostic, Ireland, acetyl CoA ligase activity, Cancers, Eire, TBX20, extra, Ribonucleic Acid, Lds, cfRNA, Circulating Nucleic, P-Health, Therapeutic, Cell-Free Ribonucleic Acid, Acas, Acute Chest Syndrome, acetate:CoA ligase (AMP-forming), ACSA, PHACS, digenic, P Health, Treatment, response, absence of corpus callosum with unusual facial appearance, hereditary, NeoplasiafalseThe European MAPPYACTS trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent MalignanciesMAPPYACTS (NCT02613962) is an international prospective precision medicine trial aiming to define tumor molecular profiles in pediatric patients with recurrent/refractory malignancies, in order to suggest the most adapted salvage treatment. From February 2016 to July 2020, 787 patients were included in France, Italy, Ireland and Spain. At least one genetic alteration leading to targeted treatment suggestion was identified in 436 patients (69%) with successful sequencing; 10% of these were considered "ready for routine use". Of 356 patients with follow-up beyond 12 months, 107 (30%) received one or more matched targeted therapies, 56% of them within early clinical trials, mainly in the AcSé-ESMART platform trial (NCT02813135). Overall, matched treatment resulted in a 17% objective response rate, those of patients with "ready for routine use" alterations was 38%. In patients with extra-cerebral tumors, 76% of actionable alterations detected in tumor tissue were also identified in circulating cell free DNA (cfDNA).2024-01-15 11:39:47EGAS000010059359606EGAD00001010928EGAC00001003276